KemPharm, Inc. (NASDAQ:KMPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday.
According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “
KMPH has been the topic of a number of other research reports. ValuEngine raised KemPharm from a “strong sell” rating to a “sell” rating in a research report on Monday, October 23rd. Oppenheimer Holdings, Inc. set a $13.00 price target on KemPharm and gave the stock a “buy” rating in a research report on Thursday, August 10th. Finally, Canaccord Genuity reissued a “buy” rating and set a $7.00 price target on shares of KemPharm in a research report on Monday, September 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. KemPharm currently has an average rating of “Buy” and an average target price of $8.05.
In other news, major shareholder Delaware Street Capital Master bought 325,888 shares of the firm’s stock in a transaction dated Thursday, September 14th. The shares were bought at an average price of $3.27 per share, with a total value of $1,065,653.76. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders bought 335,188 shares of company stock worth $1,090,088 in the last ninety days. 22.80% of the stock is owned by company insiders.
Institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp grew its position in shares of KemPharm by 17.6% in the first quarter. Bank of New York Mellon Corp now owns 22,854 shares of the specialty pharmaceutical company’s stock valued at $112,000 after purchasing an additional 3,414 shares during the last quarter. C WorldWide Group Holding A S grew its position in shares of KemPharm by 110.1% in the second quarter. C WorldWide Group Holding A S now owns 381,699 shares of the specialty pharmaceutical company’s stock valued at $1,527,000 after purchasing an additional 200,000 shares during the last quarter. Finally, Alyeska Investment Group L.P. grew its position in shares of KemPharm by 1.8% in the third quarter. Alyeska Investment Group L.P. now owns 992,338 shares of the specialty pharmaceutical company’s stock valued at $3,672,000 after purchasing an additional 17,721 shares during the last quarter. 39.36% of the stock is currently owned by institutional investors.
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with MarketBeat.com's FREE daily email newsletter.